NCT05962398
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Enrolling by Invitation
Not specifiedAges 18+ObservationalCSL Behring
~56 participants
Updated 2025-07-18 on ClinicalTrials.gov
What's tested:AAV5-hFIXco-Padua
At a glance
Recruiting sites
0 of 28 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)
Measured over From Year 5 after administration of CSL222 in parent study up to Year 15
+2 more outcomes measured
Conditions
Where it's being run
28 sites across 20 statesCalifornia4
Netherlands4
Belgium2
United Kingdom2
Arizona1
Arkansas1
Colorado1
Florida1
Study leadership
- Study Director · STUDY_DIRECTOR · CSL Behring
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of Participants With Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)From Year 5 after administration of CSL222 in parent study up to Year 15
- Percentage of Participants With SAEs and AESIsFrom Year 5 after administration of CSL222 in parent study up to Year 15
- Number of SAEs and AESIsFrom Year 5 after administration of CSL222 in parent study up to Year 15